Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia

OBJECTIVES: As the prognosis of relapsed/refractory (R/R) acute myeloid leukaemia (AML) remains poor, novel treatment strategies are urgently needed. Clinical trials have shown that chimeric antigen receptor (CAR)‐T cells for AML are more challenging than those targeting CD19 in B‐cell malignancies....

Descripción completa

Detalles Bibliográficos
Autores principales: Hasegawa, Aiko, Saito, Shoji, Narimatsu, Shogo, Nakano, Shigeru, Nagai, Mika, Ohnota, Hideki, Inada, Yoichi, Morokawa, Hirokazu, Nakashima, Ikumi, Morita, Daisuke, Ide, Yuichiro, Matsuda, Kazuyuki, Tashiro, Haruko, Yagyu, Shigeki, Tanaka, Miyuki, Nakazawa, Yozo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102137/
https://www.ncbi.nlm.nih.gov/pubmed/33976880
http://dx.doi.org/10.1002/cti2.1282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102137/
https://www.ncbi.nlm.nih.gov/pubmed/33976880
http://dx.doi.org/10.1002/cti2.1282

Ejemplares similares